ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

PTGX Company Profile and Key Details

NASDAQ : PTGX

Protagonist Therapeutics, Inc.

$55.95

17.6+45.89%

At Close 4:00 PM

$56.10

0.14+0.25%

After-Market 06:01 PM

58.23

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

PTGX Stock Price Chart

Stock Price Today

Protagonist Therapeutics, Inc. (PTGX) stock surged +45.89%, trading at $55.95 on NASDAQ, up from the previous close of $38.35. The stock opened at $50.08, fluctuating between $48.99 and $57.92 in the recent session.

Stock Snapshot

38.35

Prev. Close

50.08

Open

3.43B

Market Cap

61.38M

Number of Shares

48.99

Day Low

57.92

Day High

13.23

P/E Ratio

94.11%

Free Float in %

4.23

EPS (TTM)

5.58

Book Value

-1.17

Cash Flow per Share

5.22M

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 10, 2025	50.08	57.97	48.50	55.95	5.22M
Mar 07, 2025	38.89	39.90	37.94	38.35	1.6M
Mar 06, 2025	37.92	39.40	37.92	39.05	1.03M
Mar 05, 2025	38.78	39.64	37.67	38.45	1.51M
Mar 04, 2025	38.24	39.70	37.63	38.66	1.55M
Mar 03, 2025	40.81	42.51	37.20	38.50	2.4M
Feb 28, 2025	35.97	37.66	35.97	37.59	720.44K
Feb 27, 2025	36.04	37.21	35.95	36.34	999K
Feb 26, 2025	35.48	36.25	34.81	36.15	1.02M
Feb 25, 2025	36.04	36.82	33.70	35.09	1.61M
Feb 24, 2025	38.75	38.92	35.86	36.00	1.14M
Feb 21, 2025	39.60	39.90	38.44	38.75	659.6K
Feb 20, 2025	38.41	39.07	37.83	38.49	618.7K
Feb 19, 2025	37.82	38.65	37.50	38.53	456.61K
Feb 18, 2025	38.50	39.10	37.64	37.75	495.76K
Feb 14, 2025	38.74	39.37	38.36	38.67	368.38K
Feb 13, 2025	37.62	38.72	37.38	38.68	371.64K
Feb 12, 2025	36.45	37.54	36.34	37.42	412.75K
Feb 11, 2025	37.77	38.01	36.70	36.99	908.12K
Feb 10, 2025	39.05	39.52	37.74	37.99	704.26K

Contact Details

Newark, CA 94560-1160

United States

Website: https://www.protagonist-inc.comContact: 510 474 0170

About Company

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Frequently Asked Questions

What is the current Protagonist Therapeutics, Inc. (PTGX) stock price?

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) stock price is $55.95 in the last trading session. During the trading session, PTGX stock reached the peak price of $57.92 while $48.99 was the lowest point it dropped to. The percentage change in PTGX stock occurred in the recent session was 45.89% while the dollar amount for the price change in PTGX stock was $17.60.

PTGX's industry and sector of operation?

The NASDAQ listed PTGX is part of Biotechnology industry that operates in the broader Healthcare sector. Protagonist Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PTGX?

Ms. Abha Bommireddi
Executive Vice President of Portfolio & Program Management
Dr. Dinesh V. Patel Ph.D.
Chief Executive Officer, Pres, Sec. & Director
Mr. Mohammad Masjedizadeh
Executive Vice President & Chief Technology Officer
Dr. David Y. Liu Ph.D.
Chief R&D Strategy Officer
Mr. Matthew M. Gosling
Executive Vice President & Gen. Counsel
Dr. Richard S. Shames
Clinical Advisor
Dr. Suneel K. Gupta Ph.D.
Chief Devel. Officer
Mr. Asif Ali
Executive Vice President & Chief Financial Officer
Mr. Mohammad Masjedizadeh Ph.D.
Executive Vice President & Chief Technical Officer
Dr. Ashok Bhandari Ph.D.
Executive Vice President & Chief Drug Discovery and Preclinical Devel. Officer
Ms. Carena Spivey
Senior Vice President of HR
Dr. Scott Eric Plevy M.D.
Executive Vice President & Therapeutic Head of Gastroenterology
Dr. Richard S. Shames M.D.
Clinical Advisor
Mr. Carter J. King
Senior Vice President of Bus. Devel.

How PTGX did perform over past 52-week?

PTGX's closing price is 131.01% higher than its 52-week low of $24.22 where as its distance from 52-week high of $57.97 is -3.49%.

How many employees does PTGX have?

Number of PTGX employees currently stands at 126.

Link for PTGX official website?

Official Website of PTGX is: https://www.protagonist-inc.com

How do I contact PTGX?

PTGX could be contacted at phone 510 474 0170 and can also be accessed through its website. PTGX operates from 7707 Gateway Boulevard, Newark, CA 94560-1160, United States.

How many shares of PTGX are traded daily?

PTGX stock volume for the day was 5.22M shares. The average number of PTGX shares traded daily for last 3 months was 725.66K.

What is the market cap of PTGX currently?

The market value of PTGX currently stands at $3.43B with its latest stock price at $55.95 and 61.38M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	126
Beta	2.33
Sales or Revenue	$60.00M
5Y Sales Change%	-0.236%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology